Literature DB >> 28456972

Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.

Erik J Dasbach1,2, Elamin H Elbasha3,4.   

Abstract

Decision-analytic models for cost-effectiveness analysis are developed in a variety of software packages where the accuracy of the computer code is seldom verified. Although modeling guidelines recommend using state-of-the-art quality assurance and control methods for software engineering to verify models, the fields of pharmacoeconomics and health technology assessment (HTA) have yet to establish and adopt guidance on how to verify health and economic models. The objective of this paper is to introduce to our field the variety of methods the software engineering field uses to verify that software performs as expected. We identify how many of these methods can be incorporated in the development process of decision-analytic models in order to reduce errors and increase transparency. Given the breadth of methods used in software engineering, we recommend a more in-depth initiative to be undertaken (e.g., by an ISPOR-SMDM Task Force) to define the best practices for model verification in our field and to accelerate adoption. Establishing a general guidance for verifying models will benefit the pharmacoeconomics and HTA communities by increasing accuracy of computer programming, transparency, accessibility, sharing, understandability, and trust of models.

Mesh:

Year:  2017        PMID: 28456972     DOI: 10.1007/s40273-017-0508-2

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  23 in total

1.  Representing uncertainty: the role of cost-effectiveness acceptability curves.

Authors:  E Fenwick; K Claxton; M Sculpher
Journal:  Health Econ       Date:  2001-12       Impact factor: 3.046

2.  Comparing three software tools for implementing markov models for health economic evaluations.

Authors:  Petra Menn; Rolf Holle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  A whole-cell computational model predicts phenotype from genotype.

Authors:  Jonathan R Karr; Jayodita C Sanghvi; Derek N Macklin; Miriam V Gutschow; Jared M Jacobs; Benjamin Bolival; Nacyra Assad-Garcia; John I Glass; Markus W Covert
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

4.  Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.

Authors:  Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn
Journal:  Ann Intern Med       Date:  2015-03-17       Impact factor: 25.391

Review 5.  Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.

Authors:  Jagpreet Chhatwal; Tianhua He; Maria A Lopez-Olivo
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

6.  Changing Cycle Lengths in State-Transition Models: Challenges and Solutions.

Authors:  Jagpreet Chhatwal; Suren Jayasuriya; Elamin H Elbasha
Journal:  Med Decis Making       Date:  2016-07-01       Impact factor: 2.583

7.  Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting.

Authors: 
Journal:  Diabetes Care       Date:  2007-06       Impact factor: 19.112

8.  AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users.

Authors:  P Vemer; I Corro Ramos; G A K van Voorn; M J Al; T L Feenstra
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

9.  Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: cohort study.

Authors:  Julia Hippisley-Cox; Carol Coupland
Journal:  BMJ       Date:  2015-11-11

10.  Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial.

Authors:  Claire Williams; James D Lewsey; Andrew H Briggs; Daniel F Mackay
Journal:  Med Decis Making       Date:  2016-06-08       Impact factor: 2.583

View more
  6 in total

1.  Ahead of Our Time: Collaboration in Modeling Then and Now.

Authors:  Renée J G Arnold; Sean Ekins
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

2.  Four Aspects Affecting Health Economic Decision Models and Their Validation.

Authors:  Talitha Feenstra; Isaac Corro-Ramos; Dominique Hamerlijnck; George van Voorn; Salah Ghabri
Journal:  Pharmacoeconomics       Date:  2021-12-16       Impact factor: 4.981

3.  Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom.

Authors:  Kwame Owusu-Edusei; Cody Palmer; Olga Ovcinnikova; Giampiero Favato; Vincent Daniels
Journal:  J Health Econ Outcomes Res       Date:  2022-06-06

4.  Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA.

Authors:  Kwame Owusu-Edusei; Arijita Deb; Kelly D Johnson
Journal:  Infect Dis Ther       Date:  2022-01-27

5.  Budget impact analysis of the adoption of new hypertension guidelines in Colombia.

Authors:  Cesar Augusto Guevara-Cuellar; Victoria Eugenia Soto; María Isabel Molina-Echeverry
Journal:  Cost Eff Resour Alloc       Date:  2018-09-25

6.  TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility.

Authors:  Nasuh C Büyükkaramikli; Maureen P M H Rutten-van Mölken; Johan L Severens; Maiwenn Al
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.